OFIX Orthofix Medical Inc. Insider Trading

Director John Henneman purchases 5,000 shares at market; stock down from highs amid company's ongoing losses.

John Henneman, a director of Orthofix Medical, purchased 5,000 shares on the open market, increasing his stake by a meaningful portion. The timing is noteworthy: the stock is trading well below its recent highs, having declined over the past quarter, which is a classic setup for insider conviction purchases. However, this conviction is tempered by the company's financial reality — Orthofix is currently unprofitable with negative earnings in both the latest quarter and full-year results, even as revenue shows modest growth. Henneman's purchase history shows he has been a consistent buyer on the open market in recent months, suggesting a sustained conviction despite the company's near-term profitability challenges. This is a director with direct board-level insight putting real money into the company during a period of weakness, which could signal either genuine confidence in a turnaround or simply routine portfolio maintenance by someone with deep knowledge of ongoing strategic efforts.

LP Engine Capital Management acquires ~185k OFIX shares across three days in early May, adding to May 2026 stake.

LP Engine Capital Management, a 10% institutional owner of Orthofix Medical, deployed over $2.2 million to acquire roughly 185,000 shares across three consecutive trading days in early May. Rather than signaling insider conviction about the company's direction, this series of purchases represents a portfolio management decision by an investment fund navigating a challenging stock environment — the shares trade well below their 52-week high and the company remains unprofitable with significant net losses in both the latest quarter and full year. This is the fund's third accumulation of OFIX shares within recent months, but the prior two buys, made in late February, produced losses within both near-term and longer-term horizons, illustrating the fund's mixed track record with this specific stock. The conflicting 30-day versus 90-day outcomes from prior purchases (all five prior trades declined sharply in the month following, though one recovered over a longer period) suggest the fund is averaging down into a volatile holding rather than timing a technical bottom or fundamental inflection. Without evidence of operational improvement or positive catalyst proximity, this appears to be mechanical accumulation by an institutional holder with capital to deploy, not a vote of confidence in an imminent turnaround.

Director Capps purchased 5,000 shares over 2 days at $12.46 avg, raising stake 22.1% to 27.6K shares amid unprofitability

Director Vickie L. Capps executed 3 separate purchases totaling 5,000 shares for $62,324.00 on March 9–10, 2026, at a blended average price of $12.46, increasing her holdings by 22.1% to 27,585 shares. The purchases occurred in a context of material headwinds: Orthofix reported net income of $-22,795,000.00 in its latest quarter and was unprofitable over its most recent full fiscal year, while the stock has declined 28.5% from its 52-week high of $17.30 and fallen 21.9% over the prior 90 days. The director's transaction price of $12.46 sits 0.9% above the current price of $12.37, indicating the purchases were made at minimal premium to the filing date. The substantial increase in her absolute share count and percentage stake warrants examination of whether this reflects confidence in a turnaround or represents accumulation at depressed levels during a period of negative earnings.

Engine Capital (10% owner) buys 137,858 shares in 4 transactions for $1.7M at $12.59 avg; OFIX unprofitable with $-22.8M net income

Engine Capital's filing shows 4 separate purchases totaling 137,858 shares for $1,734,955.74, expanding its holdings from 235,177 to 373,035 shares (+58.6%). The transactions span two trading days at an average price of $12.59, which is 4.4% below the current price of $13.17 but 30.6% below the 52-week high of $18.15. This accumulation occurs while Orthofix is unprofitable (net income of $-22,795,000.00) and stock momentum has softened (90-day decline of -18.2%). Among the insider's 4 prior purchases at this same ticker, only 1 proved well-timed at the 90-day horizon; the pattern suggests mixed execution on entry timing at OFIX specifically.

Engine Capital (10% owner) bought 1,250 shares of OFIX at $11.10 on 2025-07-02; stock now $10.72, -46.4% from 52-week high.

Engine Capital purchased 1,250 shares (total value $13,881.25) at $11.10, bringing holdings to 3,546,057 shares, a modest addition to an already substantial 10% ownership stake. The timing appears unfavorable: the stock has declined 23.2% over the 90-day period and sits 46.4% below its 52-week high of $20.02, and the insider's three prior purchases at OFIX on 2025-05-07 each generated -10.9% returns within 30 days. The company remains unprofitable with a net loss of $53.1M on quarterly revenue of $193.6M, though annual revenue grew 7.1% year-over-year. This small, discretionary open-market purchase adds to a pattern of accumulation at OFIX without evident well-timed execution, warranting monitoring of whether fundamentals stabilize or deteriorate further.

Director Bazaar Alan Lee bought 2,250 shares of OFIX at $10.92 on 2025-06-04, extending a recent buying pattern amid -46.5% drawdown from 52-week high.

Bazaar Alan Lee, a director, purchased 2,250 shares at $10.92 on 2025-06-04, bringing his holdings to 30,983 shares. This represents his third consecutive open-market buy at Orthofix within a span of less than a month (prior buys on 2025-05-12 and 2025-05-09), suggesting sustained accumulation during a period of significant stock weakness—the price is currently $10.71, -46.5% from the 52-week high of $20.02, and down 37.6% over the 90-day period. However, context matters: the company reported a net loss of $53,094,000 over its most recent full fiscal year, placing it in a fundamentally challenged position despite 7.1% annual revenue growth. The director's repeated purchases at a depressed absolute price point follow a pattern with no demonstrated timing success in his prior two same-ticker buys (outcomes not yet measurable at 90 days), and his broader cross-ticker track record shows only 2 prior buys with outcomes similarly unproven at scale.

OFIX CEO Calafiore buys 10,000 shares at $12.54; stock -37.9% from 52-week high, company unprofitable with -$53.1M net income.

Calafiore Massimo, President & CEO, purchased 10,000 shares at $12.54 on 2025-05-09, increasing his holdings to 234.6K shares. The transaction occurs as Orthofix stock has declined 37.9% from its 52-week high of $20.02 and fallen 9.1% over the past 30 days. The company remains unprofitable with negative net income of -$53.1M against revenue of $193.6M, creating an environment where insider buying could reflect opportunistic accumulation at depressed levels or lack of material forward confidence. The company faces significant profitability challenges despite modest 7.1% annual revenue growth. A cluster of 2 other insiders buying within the same 14-day window suggests coordinated interest, though Calafiore's prior cross-ticker buy activity showed an average 30-day return of -16.4%, and his one prior OFIX trade (2025-03-05) also posted a -16.4% 30-day return—a pattern that suggests timing has not favored his recent accumulation.

Director Alan Lee Bazaar buys 3,990 shares of OFIX in 2 transactions (May 9–12) at blended average $12.60; third insider buying in 14 days.

Alan Lee Bazaar, a Director, executed 2 purchases totaling 3,990 shares for $50,291.77 at a blended average price of $12.60, increasing his holdings by 16.1% to 28,733 shares. This transaction is part of a cluster pattern: 2 other insiders also bought within the past 14 days. The purchases occurred when the stock was trading 37.9% below its 52-week high of $20.02 and has declined 31.4% over the past 90 days, suggesting the board-level activity coincides with significant price weakness. However, the company remains unprofitable with $-53,094,000.00 net income over its most recent full fiscal year, despite posting 7.1% annual revenue growth, which presents a mixed backdrop for evaluating the statement made by insider accumulation.

10% owner Engine Capital purchases 100,000 shares at $12.31; holdings rise to 362.2K; stock down -38.5% from 52-week high amid operating losses.

Engine Capital Management, LP, a 10% owner of Orthofix Medical, executed 3 separate purchases totaling 100,000 shares for $1,231,000.00 at $12.31 per share on 2025-05-07, increasing holdings by 38.1% from 262.2K to 362.2K shares. The purchases occur after significant recent price deterioration: the stock is trading at -38.5% from its 52-week high of $20.02 and has declined -11.8% over the past 30 days and -32.4% over 90 days. Notably, Orthofix reported a quarterly loss of $-53,094,000.00 against revenue of $193,646,000.00, and the company was unprofitable over its most recent full fiscal year, even as annual revenue grew 7.1%. The acquisition of a major block by an existing 10% owner during a period of operational losses and depressed valuation levels may attract investor scrutiny regarding the owner's assessment of the company's turnaround prospects and intrinsic value.

CEO Calafiore purchases 9,914 shares of OFIX at $17.43; holdings now 222.4K shares amid -16.1% decline from 52-week high and $-27.4M annual loss.

Massimo Calafiore, President & CEO of Orthofix Medical Inc., purchased 9,914 shares at $17.43 on 2025-03-05, increasing his holdings to 222.4K shares. The company is trading at $16.80, a -16.1% decline from the 52-week high of $20.02, and has reported a negative net income of $-27.4M over its most recent full fiscal year despite 7.1% annual revenue growth. This open-market purchase by the chief executive occurs in the context of depressed equity valuation and operational losses, providing a data point on insider positioning but without sufficient context regarding the company's turnaround trajectory or the executive's stated rationale to characterize conviction definitively.